.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Queensland Health
Deloitte
Boehringer Ingelheim
Citi
McKesson
QuintilesIMS
Daiichi Sankyo
Baxter

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,969,156

« Back to Dashboard

Which drugs does patent 5,969,156 protect, and when does it expire?


Patent 5,969,156 protects CADUET, LIPITOR, and LIPTRUZET, and is included in three NDAs. There have been three Paragraph IV challenges on Caduet.

Protection for CADUET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-four patent family members in thirty-six countries.

Summary for Patent: 5,969,156

Title: Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Abstract:Crystalline forms of atorvastatin and hydrates thereof are useful hypolipidemic and hypocholesterolemic agents.
Inventor(s): Briggs; Christopher A. (Holland, MI), Jennings; Rex A. (Holland, MI), Wade; Robert (Holland, MI), Harasawa; Kikuko (Sagamihara, JP), Ichikawa; Shigeru (Machida, JP), Minohara; Kazuo (Sagamihara, JP), Nakagawa; Shinsuke (Sagamihara, JP)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:08/945,812
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-009Jul 29, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-010Jul 29, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-011Jul 29, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-001Jan 30, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-002Jan 30, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-003Jan 30, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-004Jan 30, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-005Jan 30, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-006Jan 30, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
PfizerCADUETamlodipine besylate; atorvastatin calciumTABLET;ORAL021540-007Jan 30, 2004ABRXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,969,156

PCT Information
PCT FiledJuly 08, 1996PCT Application Number:PCT/US96/11368
PCT Publication Date:February 06, 1997PCT Publication Number: WO97/03959

International Patent Family for Patent: 5,969,156

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina003458► Subscribe
Argentina003459► Subscribe
Austria208375► Subscribe
Austria284868► Subscribe
Austria8453► Subscribe
Australia6484296► Subscribe
Australia725424► Subscribe
Bulgaria102187► Subscribe
Bulgaria63630► Subscribe
Brazil9609872► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
Chinese Patent Office
Fish and Richardson
Citi
Colorcon
Mallinckrodt
Moodys
Farmers Insurance
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot